This July (July 12–21), I joined a China–Austria–EU Summer Exchange Program. During the trip I visited Heidelberg, a historic German city, and unexpectedly came across a Pharmacy Museum inside the Heidelberg Castle complex.

The museum's exhibits focus on the evolution of German medicine and pharmacy from the 16th to the 18th century. Rows of wooden apothecary drawers, beautifully crafted glass bottles, and displays of botanical, mineral, and animal-origin materials immediately reminded me of traditional Chinese medicine (TCM) pharmacies back home. There was even a dedicated "compounding room" area with old scales, mortars, copper containers, and measuring tools-almost like a working dispensary frozen in time.

That visit sparked a question that many of us in the botanical ingredient industry are asking today:

Europe's herbal tradition and TCM share similarities in origin and practice-so what can we learn from Europe's path toward modern, regulated phytomedicines?

 

 

1) Europe's herbal tradition: long history, strong documentation

Herbal medicine has been a core part of traditional healthcare worldwide, and it remains important today across systems such as TCM, Ayurveda, and various traditional and natural medicine approaches.

In Europe-especially in Germany-herbal medicine also has a deep history and a strong written record. European herbal knowledge can be traced back to Greco-Roman times and expanded through landmark pharmacopoeial and medical works. During the Renaissance, herbalism flourished.

Later, as modern Western medicine advanced and synthetic pharmaceuticals emerged, herbal medicine lost momentum for a period. But in recent decades, with growing awareness of drug side effects and a shift toward prevention and wellness, European botanical medicine has seen a clear revival-not only culturally, but industrially and scientifically.

2) The current European market: herbal products are mainstream (especially in Germany)

In recent years, herbs such as arnica, calendula, chamomile, echinacea, chaste tree (Vitex agnus-castus), agrimony, comfrey, elderflower, elecampane, fennel, lemon balm, and licorice have been commonly used across European health traditions and product categories.

Among EU countries, Germany is particularly notable-both as a major producer and as a research leader in herbal preparations. Germany is also among the countries with the most herbal medicinal products available on the market.

Beyond consumer demand, Europe's revival is supported by research output and well-known phytomedicine manufacturers. A frequently cited example is standardized Ginkgo biloba extract products developed and commercialized with modern quality controls-showing how "traditional plants" can be translated into regulated, evidence-aligned products.

 

3) Regulation is the key turning point: Europe modernized herbal medicine by standardizing it

One of Europe's most important developments has been bringing herbal products into structured regulatory pathways.

At the EU level, botanicals and related preparations are managed under the broader concept of herbal medicinal products. In 2004, the EU established a dedicated procedure for traditional herbal medicines through the Traditional Herbal Medicinal Products Directive (2004/24/EC).

 

In simple terms, the European approach sends a clear message to the industry:

Herbal products must meet defined quality and safety requirements

 

Click the picture to visit our factory and cistanche base

Traditional use can support registration, but it must be documented and traceable

 

Manufacturing must be standardized, not artisanal

Market access is built on compliance, not storytelling

Germany is often used as a practical benchmark. It places strong emphasis on:

clear raw material standards,

modern manufacturing systems,

standardized processes and testing,

reproducible quality across batches.

 

4) What Europe's experience suggests for TCM internationalization

TCM has been practiced in China for thousands of years, supported by a complete theoretical system and a large body of clinical experience. Yet globally, the market share of TCM-based products remains relatively small compared to its depth and potential.

After the EU's 2004 directive, many companies found that the "traditional" label alone was not enough-regulatory readiness became the real barrier. From Europe's development path, I see four practical insights for the globalization of TCM and Chinese botanical ingredients:

(1) Keep the "root": don't abandon TCM theory-translate it

TCM's strength is its framework (pattern differentiation, holistic formulation logic). But for international markets, the challenge is communication:
we need to translate TCM concepts into quality, safety, and function language that regulators and formulators can work with, without losing the essence.

(2) Stay open: learn from Europe's accumulated herbal experience

Europe has its own centuries of herbal practice, and many plants have well-developed usage traditions and product formats. For Chinese companies, studying this history can help us:

better understand how Europe frames botanical use,

identify product formats that fit local expectations,

build cross-cultural scientific and commercial bridges.

(3) Innovate: move up the value chain from raw materials to standardized extracts

One recurring pattern in global trade is that value often concentrates in standardization, extraction technology, and documentation, not in raw plant material alone.

For China's botanical industry, the opportunity is clear:

build robust extraction and standardization capabilities,

provide consistent specs and traceability,

support downstream brands with ready-to-formulate ingredients and documentation.

(4) Standardize management: quality systems are the "passport"

To gain long-term trust in international markets, we need:

stronger quality standards,

transparent testing,

compliance-friendly documentation,

alignment with international expectations for contaminants, identity, and consistency.

 

5) Our case: 30 years in Cistanche, and why "compliance-first" is our strategy

I'm sharing these thoughts not only as a visitor to a museum, but also as a botanical ingredient manufacturer actively searching for compliant paths.

We have specialized in Cistanche for 30 years (company background here:
https://www.xjcistanche.com/about-us).

From our perspective, entering EU/UK/USA markets is not only about finding the right story-it's about building the right evidence and compliance foundation.

 

What we focus on as a Cistanche supplier

No pesticides and no chemical fertilizers in our cultivation approach

Cistanche is a parasitic plant (Orobanchaceae) that grows by attaching to host roots and absorbing nutrients-this makes quality control and environmental management especially important

 

Our Manufacturer Specification List

Click the table to get more details

Our Cistanche tablets are legally marketed in China with NMPA approval and carry the "Blue Hat" health food mark.

 

We maintain complete testing documentation, including:

screening for 100 types of pests/diseases-related risks (as part of our internal quality management and agricultural risk control),

6 heavy metals testing with compliant results,

and other routine identity and safety assessments as required by customers.

Our goal is to offer a compliance-ready Cistanche ingredient-with the documentation and consistency that international partners expect-so that brands and formulators can develop products with more confidence.

 

6) Opening the discussion (for EU botanicals / functional ingredients professionals)

From your experience in the EU botanical and functional ingredient space:

What documentation do you consider "must-have" today for a new botanical ingredient supplier (identity, contaminants, stability, traceability, traditional use, clinical data, etc.)?

For Cistanche specifically, which positioning is more realistic for Europe right now-food supplement ingredient vs herbal medicinal pathway?

What are the most common compliance pitfalls you see when Asian botanical suppliers enter the EU market?

I'd really appreciate your insights. We're committed to long-term, standards-based development-and we're eager to learn from the European industry's best practices.